Diversion Control Homepage Diversion Control Homepage Privacy Policy Contact Us What's New Hot Items Site Map Search Diversion SiteDEA Diversion Control Program Logo and Banner

 

Federal Register Notices > Importers > Sigma Aldrich Manufacturing LLC

Notice of Application 2007


FR Doc E7-3297 [Federal Register: February 27, 2007 (Volume 72, Number 38)] [Notices] [Page 8793] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr27fe07-131]

[[Page 8793]]


DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Application

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II and prior to issuing a regulation under 21 U.S.C. 952(a) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on January 9, 2007, Sigma Aldrich Manufacturing LLC., Subsidiary of Sigma-Aldrich Company, 3500 Dekalb Street, St. Louis, Missouri 63118, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedule I and II:

Drug  Schedule
Cathinone (1235)  I
Methcathinone (1237)  I
Aminorex (1585)  I
Gamma Hydroxybutyric Acid (2010)  I
Methaqualone (2565)  I
Ibogaine (7260)  I
Lysergic acid diethylamide (7315)  I
Marihuana (7360)  I
Tetrahydrocannabinols (7370)  I
Mescaline (7381)  I
4-Bromo-2,5-dimethoxyamphetamine (7391)  I
4-Bromo-2,5-dimethoxyphenethylamine (7392)  I
4-Methyl-2,5-dimethoxyamphetamine (7395)  I
2,5-Dimethoxyamphetamine (7396)  I
3,4-Methylenedioxyamphetamine (7400)  I
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)  I
3,4-Methylenedioxy-N-ethylamphetamine (7404)  I
3,4-Methylenedioxymethamphetamine (MDMA) (7405)  I
4-Methoxyamphetamine (7411)  I
Bufotenine (7433)  I
Diethyltryptamine (7434)  I
Dimethyltryptamine (7435)  I
Psilocybin (7437)  I
Psilocyn (7438)  I
N-Ethyl-1-phenylcyclohexylamine (7455)  I
N-Benzylpiperazine (BZP) (7493)  I
Trifluoromethylphenyl Piperazine (7494)  I
Heroin (9200)  I
Normorphine (9313)  I
Etonitazene (9624)  I
Amphetamine (1100)  II
Methamphetamine (1105)  II
Methylphenidate (1724)  II
Amobarbital (2125)  II
Pentobarbital (2270)  II
Secobarbital (2315)  II
Glutethimide (2550)  II
Nabilone (7379)  II
Phencyclidine (7471)  II
Cocaine (9041)  II
Codeine (9050)  II
Diprenorphine (9058)  II
Oxycodone (9143)  II
Hydromorphone (9150)  II
Diphenoxylate (9170)  II
Ecgonine (9180)  II
Ethylmorphine (9190)  II
Hydrocodone (9193)  II
Levorphanol (9220)  II
Meperidine (9230)  II
Methadone (9250)  II
Dextropropoxyphene, bulk (non-dosage forms) (9273)  II
Morphine (9300)  II
Thebaine (9333)  II
Opium powdered (9639)  II
Oxymorphone (9652)  II
Fentanyl (9801)  II

The company plans to import the listed controlled substances for sale to research facilities for drug testing and analysis. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, D.C. 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than March 29, 2007.

This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745-46), all applicants for registration to import a basic classes of any controlled substances listed in schedule I or II are, and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied.

Dated: February 16, 2007.

Joseph T. Rannazzisi, 
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E7-3297 Filed 2-26-07; 8:45 am]

BILLING CODE 4410-09-P

NOTICE: This is an unofficial version. An official version of these publications may be obtained directly from the Government Printing Office (GPO).

 


     HOME

CONTACT US

SEARCH

BACK TO TOP